PRESS RELEASE published on 04/05/2024 at 10:17, 2 years 2 months ago APONTIS PHARMA enters five-year distribution and marketing agreement with Novartis for two asthma medications and raises forecast APONTIS PHARMA partners with Novartis for asthma medications distribution and marketing, raising forecast for 2024 financial year Distribution Agreement APONTIS PHARMA Asthma Medications Novartis Forecast Increase
BRIEF published on 04/05/2024 at 10:15, 2 years 2 months ago APONTIS PHARMA AG Enhances Forecast Following Agreement with Novartis APONTIS PHARMA AG Financial Growth Forecast Upgrade Novartis Agreement Asthma Medications
BRIEF published on 04/05/2024 at 10:15, 2 years 2 months ago APONTIS PHARMA AG améliore ses prévisions suite à un accord avec Novartis Croissance Financière APONTIS PHARMA AG Mise À Niveau Des Prévisions Accord Novartis Médicaments Contre L'asthme
PRESS RELEASE published on 04/05/2024 at 10:10, 2 years 2 months ago EQS-Adhoc: APONTIS PHARMA AG raises forecast after entering five-year distribution and marketing agreement with Novartis for two asthma medications APONTIS PHARMA AG raises forecast following agreement with Novartis for asthma medications Forecast Raise Financial Outlook APONTIS PHARMA AG Novartis Agreement Asthma Medications
BRIEF published on 03/28/2024 at 07:35, 2 years 2 months ago APONTIS PHARMA Anticipates Profitable Growth in 2024 After Restructuring APONTIS PHARMA Single Pill Combinations Financial Results 2023 Profitable Growth 2024 Restructuring Program
BRIEF published on 03/28/2024 at 07:35, 2 years 2 months ago APONTIS PHARMA prévoit une croissance rentable en 2024 après sa restructuration Résultats Financiers 2023 PHARMA APONTIS Croissance Rentable 2024 Combinaisons De Pilules Uniques Programme De Restructuration
PRESS RELEASE published on 03/28/2024 at 07:30, 2 years 2 months ago APONTIS PHARMA expects profitable growth again in 2024 APONTIS PHARMA expects profitable growth in 2024 with sales forecasted to rise to EUR 41.7 million and positive EBITDA of EUR 1.8 million. Performance and efficiency improvements drive future growth EBITDA Profitable Growth APONTIS PHARMA Sales Forecast Efficiency Improvements
PRESS RELEASE published on 02/09/2024 at 10:52, 2 years 4 months ago Original-Research: APONTIS PHARMA AG (von Montega AG): Kaufen APONTIS PHARMA AG hat ein Strategie-Update gegeben und finanzielle Details aus der Restrukturierung bekannt gegeben, was zu einer Reduktion der Break Even-Schwelle führt APONTIS PHARMA AG Strategie-Update Restrukturierung Finanzielle Details Break Even-Schwelle
PRESS RELEASE published on 02/06/2024 at 07:30, 2 years 4 months ago APONTIS PHARMA successfully completes performance and efficiency improvement program APONTIS PHARMA successfully completes performance and efficiency improvement program, reducing headcount and expenses. New go-to-market approach for Single Pill combinations to start on 1 March 2024 Pharmaceutical Company Efficiency APONTIS PHARMA Performance Improvement Single Pill Combinations
PRESS RELEASE published on 11/09/2023 at 07:30, 2 years 7 months ago APONTIS PHARMA presents details of the restructuring and efficiency program – Nine-month figures for 2023 and new sales and earnings forecast for 2023 published
Published on 06/24/2026 at 03:15, 4 hours 26 minutes ago Noram Lithium Adopts Semi-Annual Financial Reporting
Published on 06/24/2026 at 00:00, 7 hours 41 minutes ago Onco-Innovations Engages Nanosoft Polymers to Advance Polymer and Drug Delivery Development for ONC010
Published on 06/23/2026 at 23:45, 7 hours 56 minutes ago Prospect Ridge Aligns with the Market Mindset for Exclusive Live Investor Interview Discussing Game-changing 2026 Drill Programs
Published on 06/23/2026 at 23:20, 8 hours 21 minutes ago BioNxt Announces Closing of Non-brokered Private Placement of Units Pursuant to the Listed Issuer Exemption
Published on 06/23/2026 at 23:15, 8 hours 26 minutes ago EV Nickel Signs LOI Forming High-Grade Nickel Joint Venture for Shaw Dome Projects
Published on 06/24/2026 at 07:30, 11 minutes ago NAGA SECURES MICA AUTHORIZATION FOR CRYPTO-ASSET SERVICES ACROSS THE EU
Published on 06/24/2026 at 07:30, 11 minutes ago Leclanché Announces Extension of Financial Close Deadline under €74.2 Million CINEA Grant Agreement
Published on 06/24/2026 at 07:30, 11 minutes ago Leclanché annonce la prolongation du délai de clôture financière dans le cadre de la convention de subvention CINEA d'un montant de 74,2 millions d'euros
Published on 06/24/2026 at 07:30, 11 minutes ago Carvolix Secures New EUR 10m Tranche, Bringing Total Financing to EUR 20m as Part of its EUR 30m Programme
Published on 06/24/2026 at 07:30, 11 minutes ago Carvolix sécurise une nouvelle tranche de 10 M€, portant à 20 M€ de financement dans le cadre de son programme de 30 M€
Published on 06/23/2026 at 19:47, 11 hours 54 minutes ago GROUPE SFPI: reorganisation de la Direction Générale
Published on 06/23/2026 at 19:47, 11 hours 54 minutes ago GROUPE SFPI: General management reorganisation
Published on 06/23/2026 at 19:10, 12 hours 31 minutes ago GUILLEMOT CORPORATION > EVOLUTION DE LA GOUVERNANCE A COMPTER DU 23 JUIN 2026
Published on 06/23/2026 at 19:10, 12 hours 31 minutes ago GUILLEMOT CORPORATION: Changes to Corporate Governance Effective June 23, 2026
Published on 06/23/2026 at 18:32, 13 hours 9 minutes ago Communiqué sur la demande de radiation auprès d'Euroclear des Droits à Complément de Prix
